^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastric Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Margenza (margetuximab-cmkb) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

    Excerpt:
    Determine the recommended expansion phase dose of margetuximab in combination with pembrolizumab [ Time Frame: 9 months ] Characterize maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of margetuximab when administered in combination with pembrolizumab
    Trial ID:
    NCT02689284
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

    Published date:
    10/09/2018
    Excerpt:
    HER2+, PD-L1-unselected, 2nd line GEA pts post T progression received Margetuximab (M)…+ Pembrolizumab (P)...Our results suggest that M+P is well tolerated and has encouraging preliminary activity in 2nd line HER2+ GEA.
    DOI:
    10.1093/annonc/mdy282.046
    Trial ID:
    NCT02689284